Claims
- 1. A method for inhibiting and preventing a malignant cell phenotype comprising administering to cells a low dose of a nitric oxide mimetic.
- 2. The method of claim 1 wherein the cells are in a subject at risk for or suffering from a malignant cell phenotype.
- 3. The method of claim 1 or 2 wherein administration of the nitric oxide mimetic inhibits metastases and development of resistance to antimalignant therapeutic modalities in the cells.
- 4. The method of claim 1 or 2 wherein administration of the nitric oxide mimetic inhibits development of a more aggressive malignant cell phenotype in the cells upon administration of an anti-VEGF agent.
- 5. The method of claim 1 or 2 wherein administration of the nitric oxide mimetic inhibits development of a malignant cell phenotype in cells exposed to factors which lower cellular nitric oxide mimetic activity.
- 6. The method of claim 1 or 2 wherein more than one nitric oxide mimetic is administered.
- 7. The method of claim 6 wherein an NO donor is co-administered with a compound that inhibits cyclic nucleotide degradation.
- 8. A method for increasing efficacy of an antimalignant therapeutic modality against cancer cells comprising administering to the cells a low dose of a nitric oxide mimetic.
- 9. A formulation for inhibiting and preventing a malignant cell phenotype comprising a nitric oxide mimetic in an amount which increases, restores or maintains nitric oxide mimetic activity of cells to a level which prevents or inhibits a malignant cell phenotype.
- 10. The formulation of claim 9 wherein the amount of nitric oxide mimetic delays development or reduces development of drug tolerance to the nitric oxide mimetic or side effects.
- 11. The formulation of claim 9 comprising more then one nitric oxide mimetic.
- 12. The formulation of claim 11 wherein the nitric oxide mimetics include an NO donor and a compound that inhibits cyclic nucleotide degradation.
- 13. A method for inhibiting and preventing a malignant cell phenotype in an animal comprising administering to an animal in need thereof a low dose of a nitric oxide mimetic.
- 14. The method of claim 13 wherein more than one nitric oxide mimetic is administered.
- 15. The method of claim 14 wherein an NO donor is co-administered with a compound that inhibits cyclic nucleotide degradation.
- 16. The method of claim 13 wherein administration of the nitric oxide mimetic inhibits tumor metastases and development of resistance to antimalignant therapeutic modalities in cells in the animal.
- 17. The method of claim 13 wherein administration of the nitric oxide mimetic inhibits development of a more aggressive malignant cell phenotype in cells in the animal upon administration of an anti-VEGF agent to the animal.
- 18. The method of claim 13 wherein administration of the nitric oxide mimetic inhibits development of a malignant cell phenotype in animals exposed to factors which lower cellular nitric oxide mimetic activity.
- 19. A method of treating cancer in a subject comprising administering to a subject in need thereof a low dose of a nitric oxide mimetic.
- 20. The method of claim 19 wherein more than one nitric oxide mimetic is administered.
- 21. The method of claim 20 wherein an NO donor is co-administered with a compound that inhibits cyclic nucleotide degradation.
- 22. The method of claim 19 wherein the cancer is prostate cancer.
- 23. A method for prophylactically inhibiting and preventing a malignant cell phenotype in animals at high risk for developing cancer comprising administering to the animals a low dose of a nitric oxide mimetic.
- 24. The method of claim 23 wherein more than one nitric oxide mimetic is administered.
- 25. The method of claim 24 wherein an NO donor is co-administered with a compound that inhibits cyclic nucleotide degradation.
- 26. A method of monitoring or diagnosing the progression of a tumor in a patient comprising measuring a level of a tumor marker in the patient in the presence of a low dose of a nitric oxide mimetic.
- 27. The method of claim 26 wherein the tumor marker is prostate specific antigen.
- 28. A method for decreasing a tumor marker level in a patient comprising administering to the patient a low dose of a nitric oxide mimetic.
- 29. The method of claim 28 wherein the tumor marker is prostate specific antigen.
- 30. The use of a nitric oxide mimetic for preparation of a medicament for increasing, restoring or maintaining nitric oxide mimetic activity of cells to a level which increases efficacy of an antimalignant therapeutic modality against cancer cells.
- 31. The use of a nitric oxide mimetic for preparation of a medicament for increasing, restoring or maintaining nitric oxide mimetic activity of cells to a level which inhibits and prevents a malignant cell phenotype in an animal.
- 32. The use of a nitric oxide mimetic for preparation of a medicament for increasing, restoring or maintaining nitric oxide mimetic activity of cells to a level which prophylactically inhibits and prevents a malignant cell phenotype in an animal at high risk for developing cancer.
Parent Case Info
[0001] This application claims the benefit of priority from U.S. Provisional Application Ser. No. 60/277,469 filed Mar. 21, 2001, and U.S. Provisional Application Ser. No. 60/199,757 filed Apr. 26, 2000.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60277469 |
Mar 2001 |
US |
|
60199757 |
Apr 2000 |
US |